TransCode Therapeutics (NASDAQ:RNAZ) Stock Rating Reaffirmed by HC Wainwright

TransCode Therapeutics (NASDAQ:RNAZGet Free Report)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research report issued to clients and investors on Wednesday, Benzinga reports. They currently have a $3.00 price objective on the stock. HC Wainwright’s target price points to a potential upside of 82.93% from the company’s previous close.

TransCode Therapeutics Trading Up 13.1 %

RNAZ stock opened at $1.64 on Wednesday. TransCode Therapeutics has a 52 week low of $0.42 and a 52 week high of $223.60. The company has a market capitalization of $10.86 million, a price-to-earnings ratio of 0.00 and a beta of -0.36. The firm’s 50-day moving average is $0.85 and its two-hundred day moving average is $3.08.

Institutional Trading of TransCode Therapeutics

A hedge fund recently raised its stake in TransCode Therapeutics stock. Sabby Management LLC grew its stake in shares of TransCode Therapeutics, Inc. (NASDAQ:RNAZFree Report) by 32.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 250,309 shares of the company’s stock after buying an additional 61,872 shares during the quarter. Sabby Management LLC owned about 12.33% of TransCode Therapeutics worth $126,000 as of its most recent filing with the Securities and Exchange Commission.

About TransCode Therapeutics

(Get Free Report)

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.

See Also

Receive News & Ratings for TransCode Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransCode Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.